Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INCY NASDAQ:NBIX NASDAQ:ONEM NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINCYIncyte$67.86-1.6%$67.12$53.56▼$83.95$13.14B0.681.94 million shs1.56 million shsNBIXNeurocrine Biosciences$132.02-1.6%$125.84$84.23▼$157.98$13.07B0.241.15 million shs757,716 shsONEM1Life Healthcare$16.47$16.09$5.94▼$17.55$3.37B1.993.22 million shs523,503 shsUTHRUnited Therapeutics$292.01-1.8%$300.42$266.98▼$417.82$13.17B0.53442,719 shs322,671 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINCYIncyte0.00%-1.06%-0.60%+16.58%+3.92%NBIXNeurocrine Biosciences0.00%-1.08%+3.70%+30.22%-8.73%ONEM1Life Healthcare0.00%0.00%0.00%0.00%0.00%UTHRUnited Therapeutics0.00%-1.19%+0.10%+2.56%-11.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINCYIncyte4.5374 of 5 stars2.15.00.02.81.83.33.1NBIXNeurocrine Biosciences4.4592 of 5 stars3.43.00.02.92.42.51.9ONEM1Life HealthcareN/AN/AN/AN/AN/AN/AN/AN/AUTHRUnited Therapeutics4.9862 of 5 stars4.35.00.04.63.43.32.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINCYIncyte 2.22Hold$74.479.74% UpsideNBIXNeurocrine Biosciences 2.87Moderate Buy$163.9124.15% UpsideONEM1Life Healthcare 0.00N/AN/AN/AUTHRUnited Therapeutics 2.69Moderate Buy$383.0831.19% UpsideCurrent Analyst Ratings BreakdownLatest ONEM, UTHR, INCY, and NBIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025INCYIncyteJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$68.00 ➝ $67.007/10/2025NBIXNeurocrine BiosciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$182.007/10/2025UTHRUnited TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$348.00 ➝ $328.007/9/2025NBIXNeurocrine BiosciencesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$152.00 ➝ $174.007/8/2025UTHRUnited TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$350.00 ➝ $330.006/30/2025UTHRUnited TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$410.00 ➝ $385.006/23/2025INCYIncyteRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetSector Perform ➝ Sector Perform$67.006/16/2025INCYIncyteStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$75.00 ➝ $107.006/11/2025UTHRUnited TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$321.00 ➝ $315.006/3/2025INCYIncyteCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/3/2025INCYIncyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$61.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINCYIncyte$4.24B3.10$0.55 per share122.58$17.90 per share3.79NBIXNeurocrine Biosciences$2.36B5.55$3.38 per share39.06$25.58 per share5.16ONEM1Life Healthcare$1.05B3.22N/AN/A$9.06 per share1.82UTHRUnited Therapeutics$2.88B4.58$28.41 per share10.28$144.34 per share2.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINCYIncyte$32.62M$0.32212.0710.380.570.48%2.77%1.77%7/29/2025 (Estimated)NBIXNeurocrine Biosciences$341.30M$2.9544.7520.401.3512.68%11.81%8.59%7/30/2025 (Estimated)ONEM1Life Healthcare-$254.64M-$2.01N/AN/AN/A-38.05%-24.58%-15.62%N/AUTHRUnited Therapeutics$1.20B$25.0611.6510.626.3140.44%19.33%16.73%7/30/2025 (Estimated)Latest ONEM, UTHR, INCY, and NBIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025NBIXNeurocrine Biosciences$0.97N/AN/AN/A$653.09 millionN/A7/30/2025Q2 2025UTHRUnited Therapeutics$6.89N/AN/AN/A$802.13 millionN/A7/29/2025Q2 2025INCYIncyte$1.38N/AN/AN/A$1.15 billionN/A5/5/2025Q1 2025NBIXNeurocrine Biosciences$0.70$0.08-$0.62$0.08$587.06 million$572.60 million4/30/2025Q1 2025UTHRUnited Therapeutics$6.29$6.63+$0.34$6.63$726.82 million$794.40 million4/29/2025Q1 2025INCYIncyte$1.01$1.16+$0.15$0.80$996.17 million$1.05 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINCYIncyteN/AN/AN/AN/AN/ANBIXNeurocrine BiosciencesN/AN/AN/AN/AN/AONEM1Life HealthcareN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINCYIncyte0.012.042.00NBIXNeurocrine BiosciencesN/A3.133.02ONEM1Life Healthcare0.202.092.06UTHRUnited TherapeuticsN/A5.465.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINCYIncyte96.97%NBIXNeurocrine Biosciences92.59%ONEM1Life Healthcare78.20%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipINCYIncyte17.80%NBIXNeurocrine Biosciences4.30%ONEM1Life Healthcare4.40%UTHRUnited Therapeutics10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINCYIncyte2,617193.57 million159.12 millionOptionableNBIXNeurocrine Biosciences1,80098.97 million94.71 millionOptionableONEM1Life Healthcare3,090204.35 million195.36 millionOptionableUTHRUnited Therapeutics1,30545.11 million40.46 millionOptionableONEM, UTHR, INCY, and NBIX HeadlinesRecent News About These CompaniesUnited Therapeutics Corporation (NASDAQ:UTHR) Shares Sold by Cerity Partners LLCJuly 20 at 3:37 AM | marketbeat.comAustralianSuper Pty Ltd Buys 92,959 Shares of United Therapeutics Corporation (NASDAQ:UTHR)July 19 at 10:59 AM | marketbeat.comNew York State Common Retirement Fund Decreases Stock Holdings in United Therapeutics Corporation (NASDAQ:UTHR)July 19 at 4:22 AM | marketbeat.comMorgan Stanley Trims United Therapeutics (UTHR) Price Target, Maintains Buy RatingJuly 18 at 4:55 PM | msn.comHere's Why United Therapeutics (UTHR) is a Strong Value StockJuly 18 at 10:40 AM | zacks.comHussman Strategic Advisors Inc. Boosts Stock Holdings in United Therapeutics Corporation (NASDAQ:UTHR)July 18 at 10:38 AM | marketbeat.comUnited Therapeutics Corporation (NASDAQ:UTHR) Shares Purchased by Victory Capital Management Inc.July 18 at 6:27 AM | marketbeat.comUnited Therapeutics Corporation (NASDAQ:UTHR) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 18 at 2:57 AM | americanbankingnews.comUnited Therapeutics Corporation (NASDAQ:UTHR) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 18 at 2:56 AM | marketbeat.comUnited Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025July 16, 2025 | businesswire.comEnvestnet Asset Management Inc. Increases Stake in United Therapeutics Corporation (NASDAQ:UTHR)July 16, 2025 | marketbeat.comUnpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics StocksJuly 15, 2025 | finance.yahoo.comMQS Management LLC Purchases New Position in United Therapeutics Corporation (NASDAQ:UTHR)July 15, 2025 | marketbeat.comUnited Therapeutics Corporation (NASDAQ:UTHR) Shares Sold by M&T Bank CorpJuly 15, 2025 | marketbeat.comPaul A. Mahon Sells 11,000 Shares of United Therapeutics Corporation (NASDAQ:UTHR) StockJuly 14, 2025 | marketbeat.com6,585 Shares in United Therapeutics Corporation (NASDAQ:UTHR) Bought by Aurora Investment CounselJuly 14, 2025 | marketbeat.comEmerald Advisers LLC Sells 1,061 Shares of United Therapeutics Corporation (NASDAQ:UTHR)July 14, 2025 | marketbeat.comMorgan Stanley Cuts United Therapeutics (NASDAQ:UTHR) Price Target to $328.00July 13, 2025 | americanbankingnews.comNisa Investment Advisors LLC Sells 4,544 Shares of United Therapeutics Corporation (NASDAQ:UTHR)July 12, 2025 | marketbeat.comUnited Therapeutics’ DeciPHer-ILD Study: A New Frontier in Pulmonary Hypertension ResearchJuly 11, 2025 | tipranks.comWhy United Therapeutics (UTHR) is a Top Growth Stock for the Long-TermJuly 11, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONEM, UTHR, INCY, and NBIX Company DescriptionsIncyte NASDAQ:INCY$67.86 -1.08 (-1.57%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$67.86 0.00 (-0.01%) As of 07/18/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.Neurocrine Biosciences NASDAQ:NBIX$132.02 -2.09 (-1.56%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$131.99 -0.03 (-0.03%) As of 07/18/2025 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.1Life Healthcare NASDAQ:ONEM1Life Healthcare, Inc. operates a membership-based primary care platform under the One Medical brand. The company has developed a healthcare membership model based on direct consumer enrollment, as well as third-party sponsorship. Its membership model includes seamless access to 24/7 digital health services paired with inviting in-office care routinely covered under health insurance programs. The company also offers administrative and managerial services pursuant to contracts with physician-owned professional corporations or One Medical Entities. As of December 31, 2021, it had 703,000 consumer and enterprise members, and 33,000 At-Risk members; 182 medical offices in 25 markets; and 8,500 enterprise clients in the United States. The company was incorporated in 2002 and is headquartered in San Francisco, California.United Therapeutics NASDAQ:UTHR$292.01 -5.32 (-1.79%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$291.00 -1.01 (-0.35%) As of 07/18/2025 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
